Wells Fargo’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.79K | Sell |
4,319
-6
| -0.1% | -$10 | ﹤0.01% | 6079 |
|
|
2025
Q4 | $6.92K | Sell |
4,325
-11,991
| -73% | -$24.7K | ﹤0.01% | 6018 |
|
|
2025
Q3 | $41.8K | Sell |
16,316
-603
| -4% | -$1.9K | ﹤0.01% | 5604 |
|
|
2025
Q2 | $30.6K | Buy |
16,919
+4,626
| +38% | +$7.66K | ﹤0.01% | 5666 |
|
|
2025
Q1 | $25K | Sell |
12,293
-145
| -1% | -$541 | ﹤0.01% | 5635 |
|
|
2024
Q4 | $74.4K | Buy |
12,438
+872
| +8% | +$7.29K | ﹤0.01% | 5349 |
|
|
2024
Q3 | $113K | Buy |
11,566
+3,211
| +38% | +$43.1K | ﹤0.01% | 4945 |
|
|
2024
Q2 | $171K | Buy |
8,355
+662
| +9% | +$22.2K | ﹤0.01% | 4617 |
|
|
2024
Q1 | $347K | Buy |
7,693
+2,829
| +58% | +$135K | ﹤0.01% | 4129 |
|
|
2023
Q4 | $230K | Buy |
4,864
+182
| +4% | +$10.1K | ﹤0.01% | 4383 |
|
|
2023
Q3 | $190K | Sell |
4,682
-154
| -3% | -$15.6K | ﹤0.01% | 4385 |
|
|
2023
Q2 | $515K | Buy |
4,836
+1,860
| +63% | +$619K | ﹤0.01% | 3920 |
|
|
2023
Q1 | $888K | Buy |
2,976
+1,880
| +172% | +$803K | ﹤0.01% | 3464 |
|
|
2022
Q4 | $377K | Sell |
1,096
-73
| -6% | -$17.6K | ﹤0.01% | 3815 |
|
|
2022
Q3 | $221K | Buy |
1,169
+117
| +11% | +$27.2K | ﹤0.01% | 4188 |
|
|
2022
Q2 | $222K | Buy |
1,052
+193
| +22% | +$40.6K | ﹤0.01% | 4220 |
|
|
2022
Q1 | $288K | Sell |
859
-373
| -30% | -$108K | ﹤0.01% | 4775 |
|
|
2021
Q4 | $400K | Buy |
1,232
+619
| +101% | +$266K | ﹤0.01% | 4837 |
|
|
2021
Q3 | $298K | Buy |
613
+22
| +4% | +$9.67K | ﹤0.01% | 4935 |
|
|
2021
Q2 | $275K | Sell |
591
-195
| -25% | -$106K | ﹤0.01% | 4898 |
|
|
2021
Q1 | $542K | Sell |
786
-1,148
| -59% | -$924K | ﹤0.01% | 4639 |
|
|
2020
Q4 | $1.43M | Buy |
1,934
+1,175
| +155% | +$915K | ﹤0.01% | 3751 |
|
|
2020
Q3 | $526K | Sell |
759
-200
| -21% | -$150K | ﹤0.01% | 4299 |
|
|
2020
Q2 | $813K | Buy |
959
+447
| +87% | +$292K | ﹤0.01% | 3975 |
|
|
2020
Q1 | $184K | Sell |
512
-533
| -51% | -$192K | ﹤0.01% | 4741 |
|
|
2019
Q4 | $244K | Buy |
1,045
+350
| +50% | +$35.2K | ﹤0.01% | 4830 |
|
|
2019
Q3 | $78K | Buy |
695
+673
| +3,059% | +$106K | ﹤0.01% | 5417 |
|
|
2019
Q2 | $3K | Sell |
22
-3
| -12% | -$508 | ﹤0.01% | 6103 |
|
|
2019
Q1 | $4K | Buy |
25
+6
| +32% | +$740 | ﹤0.01% | 5766 |
|
|
2018
Q4 | $1K | Hold |
19
| – | – | ﹤0.01% | 6257 |
|
|
2018
Q3 | $2K | Hold |
19
| – | – | ﹤0.01% | 6218 |
|
|
2018
Q2 | $3K | Buy |
+19
| New | +$2.9K | ﹤0.01% | 6134 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
Wells Fargo's BTAI Position: Q1 2026 in Review
Wells Fargo reduced its BioXcel Therapeutics (BTAI) stake by 0.14% in Q1 2026, selling an estimated $10 and leaving 4,319 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #6079.
Wells Fargo first reported a position in BTAI in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.43M in Q4 2020. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- Wells Fargo held 4,319 shares of BioXcel Therapeutics worth $5.79K as of Q1 2026.
- Wells Fargo sold 6 BioXcel Therapeutics shares in Q1 2026, an estimated $10.
- BioXcel Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6079 holding.
- Wells Fargo first reported a position in BioXcel Therapeutics in Q2 2018 and has held it in 32 quarters since.
- Wells Fargo's BioXcel Therapeutics position peaked at $1.43M in Q4 2020.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.